Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 28, 2013. The report details a share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 558,000 Ordinary Shares of 25 pence each.
- Purchase Date: November 28, 2013.
- Price Range: Highest price paid was 1,617.00 pence per share; lowest price paid was 1,608.50 pence per share.
- Treasury Holdings (Settled): 509,932,909 shares (9.49% of total issued share capital).
- Treasury Holdings (Including Unsettled): 511,355,909 shares (10.52% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,861,747,606 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 558,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.52% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (4,861,747,606) for calculating disclosure thresholds under Financial Conduct Authority rules.
- Confirm the current percentage of voting rights held in Treasury (10.52% including unsettled shares).
- Review the price paid per share (approx. 1,612.75 pence average) against market prices on November 28, 2013.
- Note that this filing does not contain operational or financial performance data for the period.